Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
Ligia Yukie SassakiDaniela Oliveira MagroRogério Saad HossneJulio Pinheiro BaimaCristina FloresLucianna Motta CorreiaLívia Medeiros Soares CelaniMaria De Lourdes De Abreu FerrariPatricia ZachariasMarley Ribeiro FeitosaCarlos Henrique Marques Dos SantosManoel Alvaro de Freitas Lins NetoAbel Botelho QuaresmaSérgio Figueiredo de Lima JÚniorGraciana Bandeira Salgado De VasconcelosOrnella Sari CassolArlene Dos Santos PintoGustavo KurachiFrancisco de Assis Goncalves FilhoRodrigo Galhardi GaspariniThaísa Kowalski FurlanWilson Roberto CatapaniClaudio Saddy Rodrigues CoyVivian De Souza MenegassiMarilia Majeski ColomboRenata de Sá Brito FrÓesFábio Vieira TeixeiraAntonio Carlos da Silva MoraesGenoile Oliveira SantanaJosé Miguel Luz ParenteEduardo Garcia VilelaNatália Souza Freitas QueirozPaulo Gustavo Kotzenull nullPublished in: BMC gastroenterology (2022)
IFX was associated with higher rates of clinical remission after 1 year in comparison to ADA. Non-prior exposure to biological therapy and early response to anti-TNF treatment were associated with higher rates of clinical and endoscopic remission.